Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Senzime

4,51 SEK

+0,11 %

Mindre end 1K følgere

SEZI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
+0,11 %
-9,90 %
-16,57 %
-10,44 %
-26,75 %
-19,55 %
-38,29 %
-80,14 %
-24,09 %

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Læs mere
Markedsværdi
708,25 mio. SEK
Aktieomsætning
296,6 t SEK
Omsætning
104,02 mio.
EBIT %
-117,84 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
22.4
2026

Delårsrapport Q1'26

19.5
2026

Generalforsamling '26

16.7
2026

Delårsrapport Q2'26

Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse19.2.2026, 08.35

Redeye: Senzime (Q4 Review): Solid report and a positive 2026 outlook

Senzime
Pressemeddelelse19.2.2026, 08.00

Senzime launches TetraCom connectivity platform enabling universal transmission of anesthesia data

Senzime
Pressemeddelelse18.2.2026, 10.30

Redeye: Senzime (Q4 Initial take): Sales spot on to our estimate

Senzime

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse18.2.2026, 07.30

Senzime Q4 2025: Accelerated growth and continued clear path to profitability

Senzime
Selskabsmeddelelse18.2.2026, 07.30

Senzime secures credit line facility of 50 MSEK

Senzime
Pressemeddelelse11.2.2026, 12.45

Invitation to presentations of Senzime’s Q4 and Year-End Report 2025

Senzime
Pressemeddelelse21.1.2026, 08.30

Senzime secures major Ivy League US hospital system contract

Senzime
Pressemeddelelse17.12.2025, 07.45

Senzime’s Next-generation TetraGraph system receives regulatory approval in Japan

Senzime
Pressemeddelelse10.12.2025, 12.30

Senzime unveils the next set of innovations in neuromuscular monitoring with the launch of EMGINE Sirius

Senzime
Pressemeddelelse9.12.2025, 08.00

Senzime secures major TetraGraph order from leading UK NHS hospital system

Senzime
Pressemeddelelse19.11.2025, 07.09

BioStock: Video from Senzime's presentation at BioStock Life Science Summit 2025

Senzime
Pressemeddelelse11.11.2025, 12.00

Senzime to Present at Redeye and BioStock Investor Conferences

Senzime
Pressemeddelelse3.11.2025, 13.45

Nomination Committee for Senzime Annual General Meeting 2026

Senzime
Pressemeddelelse30.10.2025, 13.49

Redeye: Senzime (Q3 Review) - In the right direction

Senzime
Selskabsmeddelelse29.10.2025, 07.30

SENZIME Q3 2025: STRONG GROWTH AND CLEAR STEPS TOWARDS PROFITABILITY

Senzime
Pressemeddelelse23.10.2025, 09.00

Invitation to presentations of Senzime’s third quarter 2025 report

Senzime
Pressemeddelelse8.10.2025, 11.00

Senzime launches EMGINE, the next-generation software suite advancing neuromuscular monitoring

Senzime
Pressemeddelelse3.10.2025, 12.30

Senzime welcomes new European pediatric guidelines recommending EMG-based neuromuscular monitoring

Senzime
Pressemeddelelse17.9.2025, 11.15

Senzime Awarded Contract to Supply the U.S. Department of Defense and Walter Reed National Military Medical Center

Senzime
Pressemeddelelse12.9.2025, 08.00

Senzime to Present at Pareto Securities’ 16th Annual Healthcare Conference

Senzime
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.